Two pivotal studies [13, 14] demonstrated improved OS following the initiation of first-line chemotherapy in patients with HER2− ABC patients who received perioperative anthracycline-based regimens; however, to our knowledge, no reports have documented a significant improvement in OS from the initiation of first-line chemotherapy for HER2− ABC that relapsed after perioperative anthracycline- and/or taxane-based therapy, in contrast to the findings in HER2-positive ABC patients [15]. Here, ERBB2 is linked to aneurysmal bone cyst.